KRAS and cancer: Clinically relevant findings included: BRAF [OR(95%CI) = 1.65(1.24–2.18), FDR = 0.04] and KRAS [OR(95%CI) = 1.41(1.22–1.63), FDR = 0.001] mutations in CRC MSS, which were both previously reported; FBXW7 mutations suppressing PM in APAD and UCEC SEROUS despite its pro-metastatic role in other cancers; and CTCF mutations promoting PM in PRAD and LUSC (Fig. 3e).